| Literature DB >> 14586140 |
Abstract
Ifosfamide is relatively well tolerated but it can be associated occasionally with life-threatening complications such as arrhythmias and heart failure, severe encephalopathy and hemorrhagic cystitis. Mesna administration can control the urothelial toxicity of ifosfamide, but it is without effect on the other complications. Other preventive measures, such as amifostine or methylene blue administration, have not yet been adequately evaluated in a sufficient number of patients. Clinicians prescribing ifosfamide, especially in high doses, should be watchful for early signs of toxicity in order to discontinue ifosfamide administration soon enough to avoid development of major toxicity. Copyright 2003 S. Karger AG, BaselEntities:
Mesh:
Substances:
Year: 2003 PMID: 14586140 DOI: 10.1159/000073351
Source DB: PubMed Journal: Oncology ISSN: 0030-2414 Impact factor: 2.935